Tandem Diabetes Care Inc (OQ:TNDM)
Business Focus: Medical Equipment, Supplies & Distribution
| Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
| See Regulatory Filings on SEC | |
| Company Contact | |
| Address: | 12400 High Bluff Drive SAN DIEGO CA 92130 |
| Tel: | N/A |
| Website: | https://www.tandemdiabetes.com |
| IR: | See website |
| Key People | ||
| Leigh A. Vosseller Chief Financial Officer, Executive Vice President, Treasurer | David B. Berger Chief Operating Officer, Executive Vice President | Susan M. Morrison Executive Vice President, Chief Administrative Officer |
| Elizabeth A. Gasser Executive Vice President, Chief Strategy Officer | Brian B. Hansen Chief Commercial Officer, Executive Vice President | Shannon M. Hansen Senior Vice President, Chief Compliance Officer, General Counsel, Chief Privacy Officer and Secretary |
| James A. Leal Senior Vice President - Operations | Rick Carpenter Chief Technical Officer | |
| Business Overview |
| Tandem Diabetes Care, Inc. is a medical device company. The Company is focused on the design, development, and commercialization of technology solutions for people living with diabetes. It manufactures and sells the t:slim X2 insulin pump with Control-IQ technology. Its manufacturing, sales, and support activities principally focus on its flagship pump platform, the t:slim X2, and its complementary product offerings. Its t:slim X2 is based on the Company's technology platform and is the smallest durable insulin pump available in the United States. The Company has commercially offered two different automated insulin dosing (AID) algorithms on t:slim X2, including Control-IQ technology, which is an advanced hybrid-closed loop feature, designed to help increase a user's time in their targeted glycemic range. It was cleared by the Food and Drug Administration (FDA) to deliver automatic correction boluses in addition to adjusting insulin to help prevent high and low blood sugar. |
| Financial Overview |
| For the three months ended 31 March 2023, Tandem Diabetes Care Inc revenues decreased 4% to $169.4M. Net loss increased from $14.7M to $123.9M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Other Selling, general and administ. increase of 23% to $75.7M (expense), Research and development - Balancing val increase of 28% to $36.7M (expense). |
| Employees: | 2,600 as of Dec 31, 2022 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | $1,365M as of Mar 31, 2023 |
| Annual revenue (TTM): | $794.69M as of Mar 31, 2023 |
| EBITDA (TTM): | -$191.23M as of Mar 31, 2023 |
| Net annual income (TTM): | -$203.75M as of Mar 31, 2023 |
| Free cash flow (TTM): | -$30.80M as of Mar 31, 2023 |
| Net Debt Last Fiscal Year: | N/A |
| Shares outstanding: | 64,621,839 as of Apr 28, 2023 |
| Index Membership: | S&P 600 Small Cap |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2023 INK Research Corp. All rights reserved.
US Quotes Data provided by IEX. US Quotes Data provided by IEX. Company fundamental sourced from © Refinitiv. Click for restrictions. © Refinitiv. All rights reserved. Republication or redistribution of Refinitiv, including by framing or similar means, is prohibited without the prior written consent of Refinitiv. Refinitiv is not liable for any errors or delays in Refinitiv content, or for any actions taken in reliance on such content.
US Quotes Data provided by IEX. US Quotes Data provided by IEX. Company fundamental sourced from © Refinitiv. Click for restrictions. © Refinitiv. All rights reserved. Republication or redistribution of Refinitiv, including by framing or similar means, is prohibited without the prior written consent of Refinitiv. Refinitiv is not liable for any errors or delays in Refinitiv content, or for any actions taken in reliance on such content.